Akitomo Sugawara1, Etsuo Kunieda. 1. Department of Radiation Oncology, Tokai University Hachioji Hospital, Hachioji, Japan.
Abstract
BACKGROUND AND OBJECTIVES: The role of adjuvant radiotherapy for resected pancreatic cancer remains controversial. The aim is to demonstrate a survival benefit of adjuvant radiotherapy for resected pancreatic cancer. METHODS: The Surveillance, Epidemiology and End Results database was used to identify patients who were diagnosed with adenocarcinoma of the pancreas from 2004 to 2009, underwent cancer-directed surgery, and received either no radiotherapy or postoperative radiotherapy. Kaplan-Meier and multivariable Cox proportional hazards analyses using a propensity score matching were conducted to determine the effect of adjuvant radiotherapy on overall and disease-specific survival. RESULTS: A total of 2,532 patients were included. The median overall and disease-specific survival were significantly longer in the adjuvant radiotherapy group than in no radiotherapy group (overall survival, 20 months vs. 16 months, respectively; disease-specific survival, 22 months vs. 18 months, respectively; both P < 0.0001). In multivariable Cox proportional analyses, adjuvant radiotherapy was associated with a significant overall and disease-specific survival benefit (both P < 0.001). CONCLUSIONS: There is a survival benefit of adjuvant radiotherapy in patients with resected pancreatic cancer. We concluded that adjuvant radiotherapy might be included in the standard treatment for resected pancreatic cancer.
BACKGROUND AND OBJECTIVES: The role of adjuvant radiotherapy for resected pancreatic cancer remains controversial. The aim is to demonstrate a survival benefit of adjuvant radiotherapy for resected pancreatic cancer. METHODS: The Surveillance, Epidemiology and End Results database was used to identify patients who were diagnosed with adenocarcinoma of the pancreas from 2004 to 2009, underwent cancer-directed surgery, and received either no radiotherapy or postoperative radiotherapy. Kaplan-Meier and multivariable Cox proportional hazards analyses using a propensity score matching were conducted to determine the effect of adjuvant radiotherapy on overall and disease-specific survival. RESULTS: A total of 2,532 patients were included. The median overall and disease-specific survival were significantly longer in the adjuvant radiotherapy group than in no radiotherapy group (overall survival, 20 months vs. 16 months, respectively; disease-specific survival, 22 months vs. 18 months, respectively; both P < 0.0001). In multivariable Cox proportional analyses, adjuvant radiotherapy was associated with a significant overall and disease-specific survival benefit (both P < 0.001). CONCLUSIONS: There is a survival benefit of adjuvant radiotherapy in patients with resected pancreatic cancer. We concluded that adjuvant radiotherapy might be included in the standard treatment for resected pancreatic cancer.
Authors: Ariella M Altman; McKenzie J White; Schelomo Marmor; Dip Shukla; Katherine Chang; Emil Lou; Christopher J LaRocca; Jane Y C Hui; Todd M Tuttle; Eric H Jensen; Jason W Denbo Journal: Cancer Control Date: 2022 Jan-Dec Impact factor: 2.339
Authors: Lee M Ocuin; Jennifer L Miller-Ocuin; Mazen S Zenati; John A Vargo; Aatur D Singhi; Steven A Burton; Nathan Bahary; Melissa E Hogg; Herbert J Zeh; Amer H Zureikat Journal: J Gastrointest Oncol Date: 2017-08
Authors: Sebastian Bachmayer; Gerd Fastner; Andrea Vaszi; Wolfgang Iglseder; Peter Kopp; Josef Holzinger; Adam Dinnewitzer; Gabriel Rinnerthaler; Simon Peter Gampenrieder; Klaus Emmanuel; Richard Greil; Felix Sedlmayer; Franz Zehentmayr Journal: Strahlenther Onkol Date: 2018-03-01 Impact factor: 3.621